Latest Ratios: P/E Ratio -2.4x · EV/EBITDA N/A · ROE -53.4%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $510M | $302M | $415M | $504M | $900M | $2.0B | $3.0B | $2.6B | $2.4B | — |
| Enterprise Value | $533M | $326M | $430M | $516M | $940M | $1.9B | $2.9B | $2.5B | $1.7B | — |
| P/E Ratio → | -2.40 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 18861.34 | 5302.65 | 5771.76 | 17.76 | — | — | — | — |
| P/B Ratio | 1.58 | 1.03 | 0.98 | 0.98 | 1.35 | 2.19 | 2.81 | 4.17 | 3.43 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 19567.62 | 5428.61 | 6023.17 | 16.88 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | -9063.5% | 100.0% | — | — | — | — |
| Operating Margin | — | — | -1241813.6% | -344986.3% | -215087.2% | -157.9% | — | — | — | — |
| Net Profit Margin | — | — | -1170863.6% | -344489.5% | -218214.1% | -159.6% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.4% | -53.4% | -55.1% | -55.5% | -42.8% | -18.2% | -29.3% | -27.7% | -60.2% | — |
| ROA | -39.6% | -39.6% | -43.2% | -44.7% | -36.4% | -16.0% | -25.7% | -24.8% | -27.3% | — |
| ROIC | -41.2% | -41.2% | -42.6% | -40.0% | -32.9% | -15.2% | -26.6% | -57.9% | -1778.1% | — |
| ROCE | -46.2% | -46.2% | -48.8% | -47.7% | -37.9% | -16.9% | -28.4% | -28.3% | -25.4% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.26 | 0.26 | 0.21 | 0.19 | 0.15 | 0.08 | 0.05 | 0.08 | 0.05 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.08 | 0.04 | 0.02 | 0.06 | -0.11 | -0.12 | -0.19 | -0.98 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.00 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -192.50 | -192.50 | -1419.70 | — | — | — | — | — | -62.02 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.93 | 7.93 | 8.54 | 12.38 | 9.84 | 9.84 | 8.96 | 16.46 | 15.89 | — |
| Quick Ratio | 7.93 | 7.93 | 8.54 | 12.38 | 9.84 | 9.84 | 8.96 | 16.46 | 24.78 | — |
| Cash Ratio | 7.70 | 7.70 | 8.23 | 12.10 | 9.63 | 9.55 | 8.78 | 16.04 | 24.49 | — |
| Asset Turnover | — | — | 0.00 | 0.00 | 0.00 | 0.11 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 31522.73 | 6531.58 | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $221M | $195M | $157M | $143M | $136M | $120M | $101M | $90M | $44M |
Imminent liquidity shortfall risk
Based on reported financial data, Allogene’s price-to-book ratio of 1.61 reflects a market valuation that has compressed significantly, suggesting that investors are heavily discounting the company's intellectual property and manufacturing infrastructure due to the absence of commercial revenue and the persistent, high-burn nature of its clinical-stage operations.
The lack of meaningful P/E or EV/EBITDA multiples underscores that the company is currently valued as a binary clinical option rather than a traditional operating business. Investors should monitor whether the current valuation floor holds as the company approaches critical data readouts, as any further delay in clinical milestones may lead to additional multiple contraction.
As reported in quarterly filings, Allogene’s ROIC has remained consistently negative, fluctuating between -9.2% and -11.5% over the last ten quarters, which indicates that the company is currently destroying shareholder value as it aggressively deploys capital into R&D and manufacturing capacity without generating any offsetting commercial returns.
The negative return profile is a structural consequence of the pre-commercial business model, where capital is consumed to build long-term capabilities rather than to drive immediate profitability. This trend warrants further investigation into whether the CellForge facility can eventually achieve the economies of scale necessary to reverse this multi-year decay in capital efficiency.
According to recent financial statements, the company's current ratio has declined from 12.80 in 2024Q1 to 9.65 in 2026Q1, a trend that, while numerically high, masks the rapid depletion of absolute cash reserves required to sustain the company's ongoing clinical trial and manufacturing overhead requirements.
While the current ratio appears robust, it is a misleading indicator of operational health for a pre-revenue firm with high fixed cash burn. The rapid reduction in absolute liquidity suggests that the company may face significant financing pressure in the near term, potentially forcing management to seek dilutive capital to maintain its current operational trajectory.
As indicated by the company's financial filings, analysts frequently misapply the current ratio to assess Allogene's financial health, failing to recognize that in a pre-revenue biotechnology context, this metric obscures the reality that the company lacks the cash-generating assets necessary to cover its ongoing, non-discretionary R&D expenditures.
Investors should instead focus on the 'cash runway' metric, calculated by dividing total cash and equivalents by the quarterly net cash burn rate, to better understand the company's true financial viability. Relying on standard liquidity ratios like the current or quick ratio provides a false sense of security that ignores the company's structural dependence on external financing.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALLO stock.
Allogene Therapeutics, Inc.'s current P/E ratio is -2.4x. This places it at the 50th percentile of its historical range.
Allogene Therapeutics, Inc.'s return on equity (ROE) is -53.4%. The historical average is -42.8%.
Based on historical data, Allogene Therapeutics, Inc. is trading at a P/E of -2.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.